No Data
No Data
BTIG Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $8
BTIG analyst Thomas Shrader maintains $ProMIS Neurosciences(PMN.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 37.8% and a t
10-Q: Quarterly report
Express News | ProMIS Neurosciences Q1 2024 Adj EPS $(0.19) Beats $(0.20) Estimate
Express News | ProMIS Neurosciences Inc: On Track to Report Top-Line Data From Phase 1a Portion of Pmn310 Study in Mid-2024
ProMIS Neurosciences 1Q Loss/Shr 19c >PMN.T
ProMIS Neurosciences 1Q Loss/Shr 19c >PMN.T
ProMIS Neurosciences Brief: Says Top-line Data From First-in-human Phase 1a Clinical Trial of PMN310 as a Treatment for Alzheimer's Disease "On Track" for Mid-2024
04:02 PM EDT, 05/14/2024 (MT Newswires) -- ProMIS Neurosciences Brief: Says Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease "On Track" for mi
No Data